MAB Discovery GmbH
MAB Discovery GmbH: Sanofi and MAB Discovery sign collaboration agreement for the development of antibodies against selected targets
DGAP-News: MAB Discovery GmbH / Key word(s): Alliance Press Release Neuried, Germany; December 14, 2015: Sanofi and MAB Discovery GmbH announced today that they have entered into a research and license agreement in the field of monoclonal antibodies. Within the scope of this collaboration, MAB Discovery will develop therapeutic antibodies for selected targets of Sanofi and thus support Sanofi in the development of antibody-based therapies. Sanofi will in return receive high-quality antibodies with the aim of identifying active substances for a number of diseases that are difficult to treat. Sanofi and MAB Discovery have agreed on a fee for the research activities. When specific milestones are achieved, the agreement provides for further performance-related payments to MAB Discovery. Financial details of the agreement were not disclosed. “Through this agreement with MAB Discovery we have found a strong collaboration in Germany to support us in bringing forward various antibody research projects with the help of its unique technology platform”, said Prof. Dr. Jochen Maas, Head of Research & Development of Sanofi Germany. “This agreement is an important confirmation for the quality of our outstanding research platform. MAB Discovery is a renowned antibody specialist who focuses primarily on previously refractory diseases with strong medical needs. Our in-vivo platform based on a new high-throughput screening processes could enable the development of best-in-class antibody therapies”, said Dr. Stephan Fischer, CEO of MAB Discovery. MAB Discovery uses its technology platform for the discovery of antibodies in vivo, which are based on natural immune responses in rabbits. Subsequently, the Company employs state-of-the-art technology for the cloning of antibodies directly from B-cells (a type of white blood cell). Applying new high-throughput screening processes, enables MAB Discovery to identify highly active antibodies. These identified antibodies cover a large number of different target structures (epitopes). The binding of medically active substances to endogenous targets is essential to fight diseases. The technology employed by MAB Discovery generates a large variety of antibodies. Of these antibodies, those with the highest possible biological effectiveness can then be selected and further developed. This technology has already been used successfully for targets that are difficult to address. One major advantage, among others, is that it requires neither time-consuming optimization of the target binding, nor the development of so-called surrogate antibodies. About MAB Discovery About Sanofi For more information please contact: For media inquiries: Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
2015-12-14 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |